Old Web
English
Sign In
Acemap
>
authorDetail
>
Ralph DeMasi
Ralph DeMasi
Durham University
Virology
Enfuvirtide
Immunology
Medicine
Immunodeficiency
4
Papers
167
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro
2006
Journal of Clinical Virology
C. Su
Tom Melby
Ralph DeMasi
P. Ravindran
Gabrielle Heilek-Snyder
Show All
Source
Cite
Save
Citations (26)
T-1249 Retains Potent Antiretroviral Activity in Patients Who Had Experienced Virological Failure while on an Enfuvirtide-Containing Treatment Regimen
2005
The Journal of Infectious Diseases
Jacob Lalezari
Nicholaos Bellos
Kunthavi Sathasivam
Gary Richmond
Calvin Cohen
Robert A. Myers
David H. Henry
Claire Raskino
Tom Melby
Hugh Murchison
Ying Zhang
Rebecca Spence
Michael L. Greenberg
Ralph DeMasi
G. Diego Miralles
Show All
Source
Cite
Save
Citations (88)
Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients
2004
Journal of Clinical Virology
David Wheeler
Jacob Lalezari
J. Michael Kilby
Joseph Wheat
John Delehanty
Ralph DeMasi
Indravadan H. Patel
Miklos Salgo
Show All
Source
Cite
Save
Citations (22)
Enfuvirtide (T-20) Cross-Reactive Glycoprotein 41 Antibody Does Not Impair the Efficacy or Safety of Enfuvirtide
2003
The Journal of Infectious Diseases
Sharon Walmsley
Keith Henry
Christine Katlama
Mark Nelson
Antonella Castagna
Jacques Reynes
Bonaventura Clotet
James Hui
Miklos Salgo
Ralph DeMasi
John Delehanty
Show All
Source
Cite
Save
Citations (31)
1